Participant flow

Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma · Source last updated 2023-09-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive oral thalidomide daily and oral prednisone every other day for 4 years in the absence of disease progression or unacceptable toxicity. prednisone: Given orally thalidomide: Given orally

   id

   FG000

   title

   Prednisone

2. description

   Patients undergo observation.

   id

   FG001

   title

   Observation

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         3

      type

      No receive treatment/lost to follow-up

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         166

      2. group Id

         FG001

         num Subjects

         166

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         165

      2. group Id

         FG001

         num Subjects

         163

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         3

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice